NextCure, Inc. Files 8-K: Material Agreement & Equity Sales
Ticker: NXTC · Form: 8-K · Filed: Jun 16, 2025 · CIK: 1661059
| Field | Detail |
|---|---|
| Company | Nextcure, Inc. (NXTC) |
| Form Type | 8-K |
| Filed Date | Jun 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, regulation-fd
TL;DR
NextCure signed a big deal and sold some stock, filing an 8-K on 6/13/25.
AI Summary
On June 13, 2025, NextCure, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. This filing also includes other events and financial statements and exhibits.
Why It Matters
This filing indicates significant corporate activity for NextCure, Inc., including a new material agreement and equity transactions, which could impact its financial position and future operations.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement and unregistered sales of equity securities, which can introduce financial and operational risks if not managed properly.
Key Players & Entities
- NextCure, Inc. (company) — Registrant
- June 13, 2025 (date) — Date of earliest event reported
- 240-399-4900 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by NextCure, Inc. on June 13, 2025?
The filing states that NextCure, Inc. entered into a material definitive agreement on June 13, 2025, but the specific details of this agreement are not provided in this document.
What type of equity securities were sold by NextCure, Inc. under unregistered sales?
The filing indicates unregistered sales of equity securities by NextCure, Inc., but does not specify the type or amount of securities sold.
What is the primary business of NextCure, Inc. according to the SIC code?
NextCure, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Where is NextCure, Inc.'s principal executive office located?
NextCure, Inc.'s principal executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705.
What is the fiscal year end for NextCure, Inc.?
NextCure, Inc.'s fiscal year ends on December 31st.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding NextCure, Inc. (NXTC).